Financial Instruments and Fair Value Measurements (Tables)

12 Months Ended

Sep. 26, 2014

Fair Value Disclosures [Abstract]

Schedule of Fair Value of Assets and Liabilities Measured on a Recurring Basis

The following tables provide a summary of the significant assets and liabilities that are measured at fair value on a recurring basis at the end of each period:

	September 26, 2014		Quoted Prices in Active Markets for Identical Assets (Level 1)		Significant Other Observable Inputs (Level 2)		Significant Unobservable Inputs (Level 3)
Assets:
Debt and equity securities held in rabbi trusts	$	35.7	$	22.9	$	12.8	$	—
	$	35.7	$	22.9	$	12.8	$	—
Liabilities:
Deferred compensation liabilities	$	15.0	$	—	$	15.0	$	—
Contingent consideration and acquired contingent liabilities	202.8		—		—		202.8
Foreign exchange forward and option contracts	0.2		0.2		—		—
	$	218.0	$	0.2	$	15.0	$	202.8

	September 27, 2013		Quoted Prices in Active Markets for Identical Assets (Level 1)		Significant Other Observable Inputs (Level 2)		Significant Unobservable Inputs (Level 3)
Assets:
Debt and equity securities held in rabbi trusts	$	35.3	$	22.6	$	12.7	$	—
Foreign exchange forward and option contracts	0.9		0.9		—		—
	$	36.2	$	23.5	$	12.7	$	—
Liabilities:
Deferred compensation liabilities	$	13.5	$	—	$	13.5	$	—
Contingent consideration	6.9		—		—		6.9
Foreign exchange forward and option contracts	1.4		1.4		—		—
	$	21.8	$	1.4	$	13.5	$	6.9

Schedule of Reconciliation of Changes in Fair Value of Contingent Consideration

Balance at September 27, 2013	$	6.9
Acquisition date fair value of acquired contingent liabilities	195.4
Accretion expense	1.1
Effect of currency rate change	(0.6		)
Balance at September 26, 2014	$	202.8

Schedule of Carrying Amount and Fair Value of Long-term Debt

The following table presents the carrying values and estimated fair values of the Company's long-term debt, excluding capital leases, as of the end of each period:

	September 26, 2014				September 27, 2013
	Carrying Value		Fair Value		Carrying Value		Fair Value
Loan payable	$	—	$	—	$	0.1	$	0.1
Variable rate receivable securitization	150.0		150.0		—		—
2.85% term loan due April 2016	3.1		3.1		—		—
3.50% notes due April 2018	300.0		290.2		299.9		293.7
Term loans due March 2021	1,990.3		1,970.4		—		—
4.00% term loan due February 2022	10.8		10.8		—		—
9.50% debentures due May 2022	10.4		14.2		10.4		14.3
5.75% notes due August 2022	900.0		907.3		—		—
8.00% debentures due March 2023	8.0		10.2		8.0		10.2
4.75% notes due April 2023	598.3		563.8		598.2		568.5

Schedules of Concentration of Risk

The following table shows net sales attributable to distributors that accounted for 10% or more of the Company's total net sales:

	Fiscal Year
	2014		2013		2012
Cardinal Health, Inc.	18	%	18	%	19	%
McKesson Corporation	17	%	15	%	14	%
Amerisource Bergen Corporation	11	%	9	%	9	%

The following table shows accounts receivable attributable to distributors that accounted for 10% or more of the Company's gross accounts receivable at the end of each period:

	September 26, 2014		September 27, 2013
Cardinal Health, Inc.	17	%	18	%
McKesson Corporation	24	%	22	%
Amerisource Bergen Corporation	13	%	14	%
CuraScript, Inc.	13	%	—

 The following table shows net sales attributable to products that accounted for 10% or more of the Company's total net sales:

	Fiscal Year
	2014		2013		2012
Optiray (CMDS)	11	%	14	%	17	%
Acetaminophen products (API)	8	%	10	%	11	%